Literature DB >> 9369811

Collagenolytic enzymes (gelatinases) and their inhibitors in human amniochorionic membrane.

S J Fortunato1, R Menon, S J Lombardi.   

Abstract

OBJECTIVE: This study was designed to investigate the presence of matrix metalloproteinase-2 (gelatinase A), matrix metalloproteinase-9 (gelatinase B), and their natural inhibitors in both cultured amniochorionic membrane and membrane obtained from women with infection-associated preterm labor. STUDY
DESIGN: Amniochorionic membranes were collected from women with documented intraamniotic infection and from women not in labor undergoing elective repeat cesarean section with no signs of infection or other complications of pregnancy. Normal membranes were cultured and exposed to endotoxin and peptidoglycan polysaccharide. Messenger ribonucleic acid expression for gelatinase A, gelatinase B, and tissue inhibitors of matrix metalloproteinase types 1 and 2 was studied with use of reverse transcriptase-polymerase chain reaction and localization of messenger ribonucleic acid was accomplished with use of in situ hybridization. Release of gelatinases from the membranes was studied with gelatin zymography. Tissue inhibitors of matrix metalloproteinase peptides were localized with use of immunocytochemistry.
RESULTS: The expression of matrix metalloproteinase types 2 and 9 was seen in amniochorionic membranes in culture. Matrix metalloproteinase-2 was seen in membranes from nonlaboring women and in women with intraamniotic infection, whereas matrix metalloproteinase-9 was seen only in membranes from women with intraamniotic infection. The matrix metalloproteinase-9 expression could also be induced by lipopolysaccharide or peptidoglycan polysaccharide stimulation in culture. In situ hybridization localized messenger ribonucleic acid for these matrix metalloproteinases to both amnion and chorion. Zymogram studies showed the activity of matrix metalloproteinase-2 in normal resting membrane and cultured membrane. Matrix metalloproteinase-9 was induced by culture conditions. Tissue inhibitor of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-2 messenger ribonucleic acid was seen in normal, infected, and cultured membranes. In situ hybridization data indicated that these messages were mainly produced by chorion, but they were also seen in amnion. Immunohistochemistry demonstrated the presence of tissue inhibitor of matrix metalloproteinase-1 and tissue inhibitor of matrix metalloproteinase-2 peptides in both amnion and chorion and in cells of the reticular layer of the matrix.
CONCLUSION: Normal amniochorionic membrane is a source of matrix metalloproteinase-2 and tissue inhibitors of matrix metalloproteinases. Culture conditions and infection induce matrix metalloproteinase-9 expression and release from amniochorion. These findings suggest that these collagenolytic enzymes may play a role in premature rupture of the membranes in infection, which can lead to preterm labor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369811     DOI: 10.1016/s0002-9378(97)70260-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  19 in total

1.  Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response.

Authors:  Roberto Romero; Piya Chaemsaithong; Steven J Korzeniewski; Adi L Tarca; Gaurav Bhatti; Zhonghui Xu; Juan P Kusanovic; Zhong Dong; Nikolina Docheva; Alicia Martinez-Varea; Bo Hyun Yoon; Sonia S Hassan; Tinnakorn Chaiworapongsa; Lami Yeo
Journal:  J Perinat Med       Date:  2016-01       Impact factor: 1.901

2.  Patterns of cytokine profiles differ with pregnancy outcome and ethnicity.

Authors:  Digna R Velez; Stephen J Fortunato; Nicole Morgan; Todd L Edwards; Salvatore J Lombardi; Scott M Williams; Ramkumar Menon
Journal:  Hum Reprod       Date:  2008-05-16       Impact factor: 6.918

3.  The role of chorionic cytotrophoblasts in the smooth chorion fusion with parietal decidua.

Authors:  O Genbačev; L Vićovac; N Larocque
Journal:  Placenta       Date:  2015-05-09       Impact factor: 3.481

4.  A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM).

Authors:  Roberto Romero; Lara A Friel; Digna R Velez Edwards; Juan Pedro Kusanovic; Sonia S Hassan; Shali Mazaki-Tovi; Edi Vaisbuch; Chong Jai Kim; Offer Erez; Tinnakorn Chaiworapongsa; Brad D Pearce; Jacquelaine Bartlett; Benjamin A Salisbury; Madan Kumar Anant; Gerald F Vovis; Min Seob Lee; Ricardo Gomez; Ernesto Behnke; Enrique Oyarzun; Gerard Tromp; Scott M Williams; Ramkumar Menon
Journal:  Am J Obstet Gynecol       Date:  2010-07-31       Impact factor: 8.661

5.  Screening of novel matrix metalloproteinases (MMPs) in human fetal membranes.

Authors:  Stephen J Fortunato; Ramkumar Menon
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

6.  Preterm premature rupture of membranes without labor is not associated with increased levels of matrix metalloproteinase-9 protein.

Authors:  D L Draper; M J Kush; W Donohoe; J Janosky; J J Latimer; R P Heine
Journal:  Prenat Neonatal Med       Date:  2001-08-01

Review 7.  Preterm prelabor rupture of the membranes: A disease of the fetal membranes.

Authors:  Ramkumar Menon; Lauren S Richardson
Journal:  Semin Perinatol       Date:  2017-08-12       Impact factor: 3.300

8.  The matrix metalloproteases and endothelin-1 in infection-associated preterm birth.

Authors:  Nicole S Olgun; Sandra E Reznik
Journal:  Obstet Gynecol Int       Date:  2010-07-26

9.  Class I to III histone deacetylases differentially regulate inflammation-induced matrix metalloproteinase 9 expression in primary amnion cells.

Authors:  Marin Poljak; Ratana Lim; Gillian Barker; Martha Lappas
Journal:  Reprod Sci       Date:  2014-01-15       Impact factor: 3.060

Review 10.  Novel concepts on pregnancy clocks and alarms: redundancy and synergy in human parturition.

Authors:  Ramkumar Menon; Elizabeth A Bonney; Jennifer Condon; Sam Mesiano; Robert N Taylor
Journal:  Hum Reprod Update       Date:  2016-06-30       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.